Histologically confirmed metastatic colorectal cancer, not amenable to curative resection
Histologically or cytologically confirmed GI malignancy for which mFOLFOX is considered an appropriate treatment (e.g., gastric cancer [GC], colorectal carcinoma, pancreatic adenocarcinoma)
Measurable, histologically/cytologically confirmed metastatic colorectal cancer (mCRC).
Pathologically documented diagnosis of colorectal adenocarcinoma.
Histologically confirmed unresectable metastatic colorectal adenocarcinoma
Histologically confirmed colorectal adenocarcinoma
Patients must have histologically or cytologically confirmed metastatic colorectal cancer.
Have histologically confirmed, locally advanced unresectable or metastatic (stage IV) colorectal adenocarcinoma
For patients with metastatic colorectal cancer:\r\n* Stage IV histologically-proven colorectal adenocarcinoma\r\n* Liver metastasis confirmed to be surgically resectable, with surgery evaluation and planned resection; may have minimal extrahepatic disease that is determined to be resectable\r\n* Tumor must be confirmed to be microsatellite stable (MSS); if not already reported at a Clinical Laboratory Improvement Act (CLIA)-certified laboratory, we will be able to perform this at Emory University\r\n* No prior immunotherapy\r\n* No cancer chemotherapy treatment  weeks prior to day  of treatment
Histologically confirmed diagnosis of colorectal adenocarcinoma
Patients must have histologically and or cytologically confirmed metastatic colorectal cancer
Participants must have histologically or cytologically confirmed adenocarcinoma of colorectal or pancreatic origin
Histologically confirmed colorectal cancer
Have a diagnosis of histologically confirmed metastatic colorectal cancer to the liver (no other sites of metastatic disease)\r\n* Histologic confirmation of a colorectal primary tumor is acceptable if accompanied by radiographic evidence of metastatic disease
Patients with histologically confirmed KRAS positive metastatic colorectal cancer
Histologically or cytologically confirmed metastatic colorectal adenocarcinoma (colon, rectal, colorectal, appendiceal cancer) or small bowel that is not resectable
Patients must have a histologically documented peritoneal carcinomatosis from either colorectal or appendiceal adenocarcinoma
Histologically or cytologically confirmed colorectal adenocarcinoma.
Histologically or cytologically confirmed colorectal adenocarcinoma
Histologically confirmed unresectable metastatic colorectal adenocarcinoma
Histologically or cytologically confirmed colorectal adenocarcinoma, with metastatic disease documented on diagnostic imaging studies
Histologically confirmed stage IV colorectal adenocarcinoma without any prior systemic treatment
Patients must have histologically or cytologically confirmed peritoneal surface malignancies from primary colorectal and appendiceal tumors
Locally confirmed dMMR or MSI-H stage IV colorectal carcinoma
Histologically confirmed recurrent or metastatic colorectal cancer
Histologically proven colorectal adenocarcinoma
Patients with histologically confirmed metastatic colorectal cancer, who have received and/or progressed on a prior oxaliplatin-based chemotherapy regimen
Histologically and/or cytologically confirmed and radiographically evaluable refractory metastatic colorectal adenocarcinoma for which regorafenib would be considered a therapeutic option
Cohort A: patients with histologically proven metastatic or locally advanced MSI colorectal adenocarcinoma
Cohort B: patients with histologically proven metastatic or locally advanced microsatellite stable (MSS) colorectal adenocarcinoma
A histologically or cytologically confirmed colorectal cancer that is metastatic, unresectable, or recurrent.
Patients must have histologically confirmed adenocarcinoma of colorectal origin that is metastatic or locally advanced and unresectable
History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease; confirmation of diagnosis must be performed by the enrolling institution
Histologically confirmed, chemo-refractory, locally advanced, recurrent or metastatic gastric (including GE junction), colorectal, or pancreatic adenocarcinoma.
Histologically or cytologically confirmed diagnosis of metastatic colorectal cancer with a product related mutation in Ras (GV, GC, GD, GR, QL, QR, QH)
Patients with histologically proven, unresectable, evaluable metastatic colorectal cancer, by RECIST criteria
Histologically confirmed colorectal cancer with at least one measurable metastatic lesion by RECIST v ., that is considered unresectable at baseline
Histologically confirmed colorectal cancer
Histologically or cytologically confirmed refractory colorectal cancer
Histologically or cytologically confirmed colorectal adenocarcinoma
Patients must have histologically confirmed, radiologically measurable metastatic or locally advanced unresectable colorectal adenocarcinoma that is amenable to image-guided biopsy; disease in previously radiated regions may not be considered measurable unless there has been demonstrated progression in the lesion
Histologically/cytologically proven colorectal carcinoma
Histologically confirmed peritoneal carcinomatosis from appendiceal, colorectal, ovarian, or primary mesothelioma, with no systemic metastases
Patients must have histologically or cytologically confirmed colorectal or pancreatic carcinoma
Histologically confirmed diagnosis of colorectal adenocarcinoma